Diabetic nephropathy

Diabetes Care

Volumn 22, Issue 1 SUPPL., 1999, Pages

  Molitch, M E ^a   DeFronzo, R A ^a   Franz, M J ^a   Keane, W F ^a   Mogensen, C E ^a   Parving, H H ^a   Steffes, M W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

DIABETES MELLITUS; DIABETIC NEPHROPATHY; HYPERTENSION; MICROALBUMINURIA; PROTEIN RESTRICTION; PROTEINURIA; SHORT SURVEY;

EID: 0032947072     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (13)

1. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care 22 (Suppl. 1):S32-S41, 1999
2. American Diabetes Association: Treatment of hypertension in diabetes (Consensus Statement). Diabetes Care 16:1394-1401, 1993
3. Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving H-H, Steffes MW, Striker GE: Screening and management of microalbuminuria in patients with diabetes mellitus. Am J Kidney Dis 25:107-112, 1995
4. DeFronzo RA: Diabetic nephropathy: etiologic and therapeutic considerations. Diabetes Rev 3:510-564, 1995
5. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
6. Jacobson HR, Striker GE for the Workshop Group: Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease. Am J Kidney Dis 25:103-106, 1995
7. Krolewski AS, Warram JH: Natural history of diabetic nephropathy. Diabetes Rev 3:446-459, 1995
8. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parvmg H-H, Passa P, Steffes MW, Striker GE, Viberti GC: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346:1080-1084, 1995
9. Nielson FS, Rossing P. Gall MA, Skott P, Smidt UM, Parving HH: Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46:1182-1188, 1997
10. Ohkubo Y, Kishikawa H, Araki E: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependenl diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
11. Reichard P, Nilsson BY, Rosenqvist V: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329: 304-309, 1993
12. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing the risk of macrovascular complications in type 2 diabetes (UKPDS 39). BMJ 317:713-720, 1998
13. UK Prospective Diabetes Study Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-653, 1998